Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

NCT01964963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19192

Last updated 2019-11-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the safety and efficacy of long-term treatment with alogliptin (Nesina) in patients with mild type 2 diabetes mellitus in the routine clinical setting.

Conditions

Interventions

DRUG

Alogliptin

Alogliptin tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-03
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01964963 on ClinicalTrials.gov